Neratinib was first approved by the U.S. Food and Drug Administration (FDA) for patients with early-stage HER2+ (overexpressed or amplified) breast cancer as an extended treatment after trastuzumab adjuvant therapy [16]. This evidence concerns the gene ERBB2 and breast carcinoma.